Sustainability Using Zero-Carbon Biopharma Facilities

The new building will create 150 new jobs and expands total production area to nearly 12,000 square meters.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

The agreement, which covers a period of five years, has been designed to offer a turnkey service to companies seeking faster time to market for ADCs and bioconjugates.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

The increasing diversity and complexity of injectable drug products is driving innovation.

The facility is on the company’s Bedford, NH campus, where another existing building will be repurposed into a Development Center of Excellence.